Halozyme Therapeutics Inc (HALO)

Fixed asset turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	810,397	762,509	752,443	685,200	643,040	566,152	478,768	464,176	435,810	457,564	408,802	329,314	267,594	199,556	180,470	164,397	195,992	202,559	181,885	177,939
Property, plant and equipment	US$ in thousands	38,108	37,466	36,050	38,544	35,101	31,068	31,368	6,943	6,791	7,163	10,132	10,366	7,293	10,252	11,169	11,752	10,855	15,398	15,079	14,542
Fixed asset turnover		21.27	20.35	20.87	17.78	18.32	18.22	15.26	66.86	64.17	63.88	40.35	31.77	36.69	19.47	16.16	13.99	18.06	13.15	12.06	12.24

December 31, 2023 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $810,397K ÷ $38,108K
= 21.27

The fixed asset turnover ratio for Halozyme Therapeutics Inc. has been fluctuating over the quarters, with the values ranging from 11.06 to 67.92.

The fixed asset turnover ratio measures how efficiently the company is utilizing its fixed assets to generate revenue. A higher ratio indicates that the company is generating more sales relative to its investment in fixed assets.

From the data provided, we can see some variability in the fixed asset turnover ratio over the past quarters, with Q1 and Q2 of 2023 showing higher ratios compared to the previous quarters. The sharp increase in Q1 2022 to 67.92 may be an anomaly or might indicate a significant increase in revenue generated per dollar of fixed assets invested.

It is important to further investigate the reasons behind these fluctuations in the fixed asset turnover ratio to assess the effectiveness of Halozyme Therapeutics Inc. in utilizing its fixed assets efficiently. Additional contextual information and industry comparisons would provide a clearer picture of the company's performance in this aspect.